Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study



Bandyopadhyay, Soham, Peter, Noel, Lakhoo, Kokila, Vieira Abib, Simone de Campos, Abdelhafeez, Hafeez, Wilson, Shaun, Pachl, Max, Martin, Benjamin, Nagras, Sonal, Sheth, Mihir
et al (show 484 more authors) (2022) Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study. BMJ OPEN, 12 (4). e054690-.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Objectives</h4>Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs.<h4>Design</h4>A multicentre, international, collaborative cohort study.<h4>Setting</h4>91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020.<h4>Participants</h4>Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer.<h4>Main outcome measure</h4>All-cause mortality at 30 days and 90 days.<h4>Results</h4>1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001).<h4>Conclusions</h4>The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally.

Item Type: Article
Uncontrolled Keywords: paediatric oncology, paediatrics, public health
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 31 Jan 2024 11:50
Last Modified: 31 Jan 2024 11:50
DOI: 10.1136/bmjopen-2021-054690
Open Access URL: https://bmjopen.bmj.com/content/12/4/e054690
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3178200